The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma

American Surgeon

Volumn 62, Issue 2, 1996, Pages 162-165

  Jain, Vikas ^b   Landry, M'Liss ^b   Levine, Edward A ^a  

^a Section of Surgical Oncology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; PREOPERATIVE TREATMENT;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0029894203     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rosen PP, Menendez-Botet CJ, Urban JA, et al. Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer. Cancer 1977;39:2194-2200.
2. Fisher B, Redmond C, Fisher ER, et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-87.
3. Jordan VC. Overview from the international conference on long-term tamoxifen therapy for breast cancer. J Natl Cancer Inst 1992;84:321-4.
4. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM. et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73:362-9.
5. American Joint Committee on Cancer. Manual for Staging of Cancer, 4th Ed. Philadelphia: J.B. Lippincott, 1992.
6. Stierer M, Rosen H, Weber R, et al. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Annals of Surgery 1993;218:13-21.
7. Bosari S, Wiley B, Hamilton W, et al. DNA measurement by image analysis of paraffin-embedded breast carcinoma tissue. Am J Clin Pathol 1991;96:698-703.
8. Heys SD, Eremin JM, Sarkar TK, et al. The role of multimodality therapy in the management of locally advanced carcinoma of the breast. J Am Coll Surg, 1994;179:493-504.
9. Calais G, Berger C, Descamps P, et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer, 1994;74:1283-1288.
10. Bonnadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimeters or more. J Natl Cancer Inst 1990;82:1539-54.
11. Morris DM, Edwards J, Gelder F. Hormonal receptors in locally advanced breast cancer: change with response to neoadjuvant chemotherapy? J Surg One 1991;46:156-8.
12. Lo SS, Wang HC, Shyr YM, Lui WY. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy? J Surg One 1994;57:94-6.
13. Li BDL, Byskosh A, Molteni A, Duda R. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg One 1994;57:71-7.
14. Allegra JC, Barlock A, Huff KK, Lippman ME. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 1980;45:792-4.
15. Young SC, Burkett RJ, Stewart C. Discrepancy in ER levels of breast carcinoma in biopsy vs mastectomy specimens. J Surg Oncol 1985;29:54-6.
16. Koh EE, Chung HC, Lee KB, et al. The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. Yonsei Med J 1992;33:137-42.
17. Charpin C, Bielh P, Duffaud F, et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to a messenger RNA expression and immunohistochemical prognostic indicators. J Natl Cancer Inst. 1994;86: 1539-1545.
18. Sanfillipo O, Ronchi E, DeMarco C, et al. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicon and vincristine. Eur J Cancer 1991;27:155-158.
19. Schneider J, Bak M, Efferth T, et al. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989;60:815-18.